The levels of expression of these coactivators, particularly SRC1 and SRC2,are higher in poorly differentiated prostate tumors or in recurrent prostate cancers andprovide cells with higher AR activity in a low-dose androgen environment (Fujimoto et al. 2001, Gregory et al.2001a). This evidence concerns the gene AR and prostate cancer.